Clinical trials: Symptoms and Signs
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02337829
- Testing
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Acerta Pharma BV
Chronic Hepatitis B
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis…
- Trial name
- NCT06384131
- Testing
- ABI-4334
- Where
- 2 sites in Moldova, New Zealand
- Volunteers
- 20 people
- Sponsor
- Assembly Biosciences
Overweight and Obesity
A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.
A Phase 1, double-blind, randomized study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of single dose and multiple doses of CG-0416 in healthy participants. HongKong Curegene Innovation Co.
- Trial name
- NCT07724431
- Testing
- CG-0416
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HongKong Curegene Innovation Co., Limited
Overweight, Obesity
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine.
- Trial name
- NCT03842202
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Kidney Diseases
Feasibility Study of a mHealth Platform for Remote Patient Monitoring of CKD and Peritoneal Dialysis Patients
The best treatment of Chronic Kidney Disease (CKD) is facilitated by early detection, when the progression of the disease can be slowed down or stopped.
- Trial name
- NCT05012020
- Testing
- mHealth Remote Monitoring platform
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- AWAK Technologies Pte Ltd
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received…
- Trial name
- NCT06136559
- Testing
- Nemtabrutinib, Ibrutinib, Acalabrutinib
- Where
- 206 sites in United States, Australia and 27 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Liver Fibroses
The EUS ShearWave Elastography Liver Fibrosis Study
The study objective is to demonstrate the clinical performance of ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS) when compared to FibroScan for evaluation of liver fibrosis.
- Trial name
- NCT04115046
- Testing
- ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS), FibroScan, ALOKA ARIETTA 850 -
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Olympus Corporation of the Americas
Myocardial Infarction
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.
- Trial name
- NCT00877903
- Testing
- Prochymal®
- Where
- 33 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Mesoblast, Inc.
HCV Infection
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
The purpose of this study is to examine the safety, tolerability, pharmacokinetics (studies how the body processes a drug), and initial activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by…
- Trial name
- NCT00725803
- Testing
- GS-9450
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 33 people
- Sponsor
- Gilead Sciences
Atrial Fibrillation
Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor
This study assess the accuracy of a blood pressure monitor designed to detect atrial fibrillation. Subjects use the blood pressure monitor on a daily basis for 30 days and compare the readings to an ECG done at the same time.
- Trial name
- TRIPPS (NCT00861354)
- Testing
- Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Microlife
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD).
- Trial name
- NCT02476994
- Testing
- Clinolipid, Intralipid
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baxter Healthcare Corporation
Cancer, Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain…
- Trial name
- NCT01006356
- Testing
- Hydromorphone HCl OROS
- Volunteers
- 141 people
- Sponsor
- Janssen Korea, Ltd., Korea
Paroxysmal Atrial Fibrillation
Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation
VITAL is a prospective, single arm, multicenter, interventional study to evaluate the safety and effectiveness of the VytronUS Ablation System (VAS) for the treatment of symptomatic paroxysmal atrial fibrillation (PAF) using low…
- Trial name
- VITAL (NCT03513029)
- Testing
- VytronUS Ablation System
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- VytronUS, Inc.
Refractory Epilepsy, Focal Seizure
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers…
- Conditions
- Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures
- Trial name
- NCT04770337
- Testing
- STARSTIM device
- Where
- 32 sites in United States, Belgium and 2 more
- Volunteers
- 127 people
- Sponsor
- Neuroelectrics Corporation
Intravenous Infiltration, Extravasation of Diagnostic and Therapeutic Materials
Optical Detection of Intravenous Infiltration
The purpose of this study is to investigate the safety and efficacy of an optical device designed and developed for monitoring the intravenous infusion site for infiltration.
- Trial name
- NCT01126710
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- CW Optics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.